Anbio Biotechnology (NASDAQ:NNNN) Shares Down 7.8% – What’s Next?

Shares of Anbio Biotechnology (NASDAQ:NNNN) traded down 7.8% during mid-day trading on Monday . The stock traded as low as $34.65 and last traded at $31.7410. 190 shares traded hands during trading, a decline of 100% from the average session volume of 44,076 shares. The stock had previously closed at $34.44.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Anbio Biotechnology from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, May 14th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, Anbio Biotechnology has an average rating of “Hold”.

Anbio Biotechnology Trading Up 6.5%

The business has a fifty day moving average of $27.59.

Anbio Biotechnology (NASDAQ:NNNN) last announced its quarterly earnings data on Tuesday, April 7th. The company reported $0.03 earnings per share for the quarter.

Anbio Biotechnology Company Profile

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.